Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy

World Journal of Surgical Oncology

Tao Li²  Lin Chen²  Ting Li²  Meiha Leong¹  Daofu Feng³ 

[1] Department of Surgery, Kiang Wu Hospital, Macao, China;Department of General Surgery, General Hospital of Chinese PLA, Beijing 100853, China;Department of General Surgery, General Hospital of Tianjin Medical University, Tianjin 300052, China

关键词: Neoadjuvant chemotherapy;    Complications;    Pathological complete response;    D2 lymphadenectomy;    Gastric cancer;   

Others  :  1146562
DOI  :  10.1186/s12957-015-0444-6

 received in 2014-10-20, accepted in 2015-01-08,  发布年份 2015

【 摘 要 】

Background

We wished to evaluate the impact of S-1 combined with oxaliplatin (SOX regimen) as neoadjuvant chemotherapy on surgical outcomes after gastrectomy with D2 lymphadenectomy.

Methods

From February 2012 to September 2013, 170 patients with American Joint Committee on Cancer (AJCC) stage II–III gastric cancer were assessed retrospectively. Eighty patients underwent neoadjuvant chemotherapy before radical gastrectomy, and 90 patients received surgical treatment with adjuvant chemotherapy. Patients received S-1 (80 mg/m²/day; days 1–14) and oxaliplatin (130 mg/m²; day 1) as neoadjuvant or adjuvant chemotherapy, and this schedule was repeated every 3 weeks. Gastrectomy with D2 lymphadenectomy was standard therapy for each patient. Surgical outcomes between the two groups were analyzed statistically.

Results

There was no significant difference in the total prevalence of complications between neoadjuvant and adjuvant groups (18.8% vs. 22.2%, P = 0.704). The most common postoperative complications were surgical site infection (6.5%) and gastrointestinal motility disorders (3.5%). The clinical response rate was 68.8%, and ten patients (12.5%) had a pathological complete response after neoadjuvant chemotherapy. The SOX regimen as neoadjuvant chemotherapy for AJCC stage II/III gastric cancer can be effective without increasing the risk of postoperative complications.

Conclusions

The SOX regimen could be a neoadjuvant chemotherapy for advanced gastric cancer worldwide in the future.

【 授权许可】

   
2015 Feng et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
• [2]Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al.. Global and regional mortalities from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2095-128.
• [3]Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortalities, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24:2137-50.
• [4]Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol. 2009; 10:903-12.
• [5]Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A et al.. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357:1810-20.
• [6]Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al.. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011; 29:4387-93.
• [7]Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006; 24:2188-96.
• [8]Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al.. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355:11-20.
• [9]Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G et al.. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29:1715-21.
• [10]Ng K, Meyerhardt JA, Fuchs CS. Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J. 2007; 13:168-74.
• [11]Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takaqi M et al.. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9:215-21.
• [12]Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N et al.. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011; 67:1423-8.
• [13]Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer 2013. doi:10.1007/s10120-013-0297-z
• [14]Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K et al.. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2010; 21:1001-5.
• [15]Liu B, Ying J, Luo C, Xu Q, Zhu L, Zhong H. S-1 combined with oxaliplatin as first line chemotherapy for Chinese advanced gastric cancer patients. Hepatogastroenterology. 2012; 59:649-53.
• [16]Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Suqimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2014; Oct 14. doi:10.1093/annonc/mdu472.
• [17]Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH et al.. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012; 48(4):518-26.
• [18]SOX regimen as neoadjuvant chemotherapy for AJCC stage II-III gastric cancer (RESONANCE), ClinicalTrials.gov, (Identifier: NCT01583361).
• [19]Japanese classification of gastric carcinoma. Third English edition. Gastric Cancer. 2011; 14:101-12.
• [20]Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-47.
• [21]Yano M, Tsujinaka T, Shiozaki H, Inoue M, Sekimoto M, Doki Y et al.. Appraisal of treatment strategy by staging laparoscopy for locally advanced gastric cancer. World J Surg. 2000; 24:1130-6.
• [22]Nam DH, Lee YK, Park JC, Lee H, Shin SK, Lee SK et al.. Prognostic value of early postoperative tumor marker response in gastric cancer. Ann Surg Oncol. 2013; 20:3905-11.
• [23]Li ZY, Shan F, Zhang LH, Bu ZD, Wu AW, Zong XL et al.. Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World J Surg Oncol. 2011; 9:110. BioMed Central Full Text
• [24]Yoshikawa T, Omura K, Kobayashi O, Nashimoto A, Takabayashi A, Yamada T et al.. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010; 36:546-51.
• [25]Oyama K, Fushida S, Kinoshita J, Makino I, Nakamura K, Hayashi H et al.. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes. J Surg Oncol. 2012; 105:535-41.
• [26]Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010; 97:643-9.
• [27]de Díaz LA, Yarnoz C, Aguilar R, Artieda C, Ortiz H. Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer. 2008; 11:96-102.
• [28]Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A et al.. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008; 359:453-62.
• [29]Sasako M. Risk factors for surgical treatment in the Dutch gastric cancer trial. Br J Surg. 1997; 84:1567-71.
• [30]Lang H, Piso P, Stukenborg C, Raab R, Jahne J. Management and results of proximal anastomotic leaks in a series of 1114 total gastrectomies for gastric carcinoma. Eur J Surg Oncol. 2000; 26:168-71.
• [31]Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K et al.. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009; 96:1015-22.
• [32]Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y et al.. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS Trial. Ann Surg Oncol. 2014; 21:213-9.
• [33]Park I, Lee JL, Ryu MH, Chang HM, Kim TW, Sum SJ et al.. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2010; 65:473-80.
• [34]Oh SY, Kwon HC, Jeong SH, Joo YT, Lee YJ, Cho S et al.. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs. 2012; 30:350-6.
• [35]Kochi M, Fujii M, Kanamori N, Mihara Y, Funada T, Tamegai H, et al. Phase II study of neoadjuvant chemotherapy with S-1 and CDDP in patients with lymph node metastatic stage II or III gastric cancer. Am J Clin Oncol. 2014; Mar 21. (PMID: 24662266).
• [36]Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R et al.. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003; 98:1521-30.